A European project on incidence, treatment, and outcome of sarcoma.
BACKGROUND
Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues and viscera. Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of origin, the incidence of sarcoma is grossly underestimated. The rarity of the disease and the variety of histological types (more than 70) or locations account for the difficulty in acquiring sufficient personal experience. In view of the above the European Commission funded the project called Connective Tissues Cancers Network (CONTICANET), to improve the prognosis of sarcoma patients by increasing the level of standardization of diagnostic and therapeutic procedures through a multicentre collaboration.


METHODS
Two protocols of epidemiological researches are here presented. The first investigation aims to build the population-based incidence of sarcoma in a two-year period, using the new 2002 WHO classification and the "second opinion" given by an expert regional pathologist on the initial diagnosis by a local pathologist. A three to five year survival rate will also be determined. Pathology reports and clinical records will be the sources of information.The second study aims to compare the effects on survival or relapse-free period - allowing for histological subtypes, clinical stage, primary site, age and gender - when the disease was treated or not according to the clinical practice guidelines (CPGs).


CONCLUSIONS
Within CONTICANET, each group was asked to design a particular study on a specific objective, the partners of the network being free to accept or not the proposed protocol. The first protocol was accepted by the other researchers, therefore the incidence of sarcoma will be assessed in three European regions, Rhone-Alpes and Aquitaine (France) and Veneto (Italy), where the geographic distribution of sarcoma will be compared after taking into account age and gender. The conformity of the clinical practice with the recommended guidelines will be investigated in a French (Rhone Alps) and Italian (Veneto) region since the CPGs were similar in both areas.
Mastrangelo
Giuseppe
G
Department of Environmental Medicine and Public Health, University of Padua, Padua, Italy.
Fadda
Emanuela
E
Cegolon
Luca
L
Montesco
Maria C
MC
Ray-Coquard
Isabel
I
Buja
Alessandra
A
Fedeli
Ugo
U
Frasson
Alvise
A
Spolaore
Paolo
P
Rossi
Carlo R
CR
D000293:Adolescent; D000328:Adult; D019058:Community Networks; D019937:Diagnostic Techniques and Procedures / Q000592:standards; D004812:Epidemiologic Methods; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D015999:Multivariate Analysis; D010865:Pilot Projects; D011159:Population Surveillance / Q000379:methods; D012107:Research Design; D012509:Sarcoma / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D017678:Sex Distribution; D012983:Soft Tissue Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
Br J Surg. 1994 Aug;81(8):1136-9
7953340
Semin Radiat Oncol. 1999 Oct;9(4):328-48
10516380
Cancer. 1999 Dec 1;86(11):2426-35
10590387
Int J Cancer. 2006 Dec 15;119(12):2922-30
17013893
Ann Oncol. 2004 Feb;15(2):307-15
14760127
Am J Clin Pathol. 2001 Oct;116(4):473-6
11601130
Eur J Cancer. 2004 Mar;40(4):543-8
14962721
Am J Epidemiol. 1984 Oct;120(4):626-34
6383024
Br J Cancer. 1991 Aug;64(2):315-20
1892759
BMJ. 1998 Jul 11;317(7151):93-4
9657781
Histopathology. 2006 Jan;48(1):3-12
16359532
Am J Surg Pathol. 2000 Feb;24(2):280-4
10680896
Acta Orthop Scand. 1994 Feb;65(1):47-50
8154283
Br J Surg. 1997 Dec;84(12):1692-6
9448617
Eur J Cancer Prev. 1997 Oct;6(5):442-66
9466116
Sarcoma. 1998;2(2):89-96
18521239
JAMA. 1997 Nov 19;278(19):1591-5
9370505
JAMA. 1988 Sep 23-30;260(12):1743-8
3045356
Eur J Surg Oncol. 2000 Sep;26(6):548-51
11184316